The question should be: How do you simplify and identify the moments that mean the most to customers?
Broadcast DTC risk info could shrink
April 1, 2014
4:00 am
FDA’s Office of Prescription Drug Promotion (OPDP) plans to research the effects that could follow changing the risk information the agency requires to be included in such direct-to-consumer ads.
US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a “pay-to-play” meeting between drug industry executives and FDA officials influenced the agency’s approval of Zohydro
Researchers have developed and tested a checklist that aims to evaluate comparative effectiveness research and distinguish real-world studies that are good enough for decision-making about treatments.
Vantage Point: Marketing Support for Clinical Trials